CLEO Diagnostics Ltd (AU:COV) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Cleo Diagnostics Ltd is expanding its ovarian cancer trial with the inclusion of Siles Health, a leading women’s health specialist network in Australia. This collaboration aims to enhance clinical insights and support market adoption of CLEO’s innovative blood test for early ovarian cancer detection. By integrating Siles Health’s expertise, CLEO is poised to advance its trial strategy and increase market awareness for its potentially life-saving diagnostic tool.
For further insights into AU:COV stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue